For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration agreement revenue | - | 0 | 0 | 0 |
| Research and development | 1,235,000 | 1,128,000 | 936,000 | 1,368,000 |
| Selling, general and administrative | 1,031,000 | 885,000 | 552,000 | 683,000 |
| Total costs and expenses | 2,266,000 | 2,013,000 | 1,488,000 | 2,051,000 |
| Operating loss | -2,266,000 | -2,013,000 | -1,488,000 | -2,051,000 |
| Total other income, net | 7,000 | 29,000 | 5,000 | 2,000 |
| Net loss | -2,259,000 | -1,984,000 | -1,483,000 | -2,049,000 |
| Basic EPS | -0.21 | -0.186 | -0.24 | -0.4 |
| Diluted EPS | -0.21 | - | - | - |
| Basic Average Shares | 10,812,419 | 10,694,424 | 6,277,848 | 5,059,736 |
| Diluted Average Shares | 10,812,419 | - | - | - |
BioCardia, Inc. (BCDA)
BioCardia, Inc. (BCDA)